← All trials
NCT05271929
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2022
- Primary completion
- Mar 10, 2024
- Completion date
- Sep 10, 2024
- First posted
- Mar 9, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 680
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- German Red CrossLead sponsor
- Erasmus University RotterdamOverall official - principal investigator
- NHS Blood and TransplantCollaborator
- University of OxfordOverall official - principal investigator
- CHU BesançonOverall official - principal investigator
- Erasmus University RotterdamOfficial
- CHU BesançonOfficial
- Erasmus University RotterdamCollaborator
- University of OxfordOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.